UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934

(Amendment No.)

Filed by the Registrant \Box

Filed by a Party other than the Registrant \boxtimes

Check the appropriate box:

- Preliminary Proxy Statement
- □ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- □ Soliciting Material Under Rule 14a-12

CytoDyn Inc.

(Name of Registrant as Specified in Its Charter)

PAUL A. ROSENBAUM JEFFREY PAUL BEATY ARTHUR L. WILMES THOMAS J. ERRICO, M.D. BRUCE PATTERSON, M.D. PETER STAATS, M.D., MBA MELISSA YEAGER CCTV PROXY GROUP, LLC

(Name of Persons(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:
□ Fee paid previously with preliminary materials:

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

Ć	2)	Form.	Schedule	or R	egistration	Statement	No.:
<u>۱</u>	-,	i onn,	Selledule	01 10	Gibtiation	Statement	110

(3)	Filing Party:
(4)	Date Filed:

The participants named herein (collectively, the "*Participants*"), have filed a definitive proxy statement and accompanying WHITE proxy card with the Securities and Exchange Commission to be used to solicit votes for the election of its slate of director nominees at the 2021 annual meeting of stockholders of CytoDyn Inc., a Delaware corporation (the "*Company*").

On October 14, 2021, the Participants issued the following press release. The press release was also posted to the Participants' website, at www.advancingll.com, and e-mailed to certain stockholders of the Company:

GROUP OF CYTODYN STOCKOLDERS COMMENTS ON DELAWARE COURT DECISION

NEW YORK — October 14, 2021 — A group of long-time stockholders (the "Investor Group") of CytoDyn Inc. ("CYDY" or the "Company") that has nominated five highly experienced director candidates to serve on the Company's Board of Directors today commented on the decision made by the Delaware Court of Chancery to deny the Investor Group's request to force the Company to allow stockholders the opportunity to vote for the Investor Group's nominees.

The Investor Group stated: "We believe strongly that the Court's ruling is fundamentally flawed and, as such, we are evaluating all possible alternatives. CYDY is very poorly managed — in addition to its complete failure to secure FDA approval for Leronlimab, it is currently being investigated by both the SEC and DOJ, and recently issued a going concern disclosure, all while the management team awards itself outsized pay packages. This company is *in desperate need of new leadership and oversight to enact sorely needed change.*"

Important Information

Paul Rosenbaum, Jeffrey Beaty, Arthur Wilmes, Thomas Errico, M.D., Bruce Patterson, M.D., Peter Staats, M.D., Melissa Yeager and CCTV Proxy Group, LLC (collectively the "Participants") have filed a definitive proxy statement and accompanying WHITE proxy card with the Securities and Exchange Commission (the "SEC") to be used in connection with the solicitation of proxies from the stockholders of CytoDyn Inc. (the "Company"). All stockholders are advised to read the definitive proxy statement and other documents related to the solicitation of proxies. The definitive proxy statement and an accompanying proxy card is available at no charge on the SEC's website at http://www.sec.gov/. In addition, the Participants will provide copies of the proxy statement, without charge, upon request. Requests for copies should be directed to the Participants' Proxy Solicitor, Okapi Partners LLC, by calling (844) 202-7428.

Disclaimer

This material does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in any jurisdiction to any person. In addition, the discussions and opinions in this press release and the material contained herein are for general information only and are not intended to provide investment advice. All statements contained in this press release that are not clearly historical in nature or that depend on future events are "forward-looking statements," which are not guarantees of future performance or results, and the words "anticipate," "believe," "expect," "may," "could," and similar expressions are generally intended to identify forward-looking statements. Forward looking statements contained in this release are based on current expectations, speak only as of the date of this press release and involve risks that may cause the actual results to be materially different. Certain information included in this material is based on data obtained from sources considered to be reliable. No representation is made with respect to the accuracy or completeness of such data. The Participants disclaim any obligation to update the information herein and reserve the right to change any of their opinions expressed herein at any time as it deems appropriate.

Contacts:

Media Mark Semer/Sam Cohen Gasthalter & Co. (212) 257-4170 cydy@gasthalter.com

Investors Bruce Goldfarb/Chuck Garske Okapi Partners (212) 297-0720 info@okapipartners.com